The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …

Objective Congenital hypothyroidism (CH), the most common neonatal metabolic disorder,
is characterized by impaired neurodevelopment. Although several candidate genes have …

Background Tumor mutational burden (TMB) is an emerging biomarker used to identify
patients who are more likely to benefit from immuno-oncology therapy. Aside from various …

Anaplastic lymphoma kinase (ALK) sequencing can identify resistance mechanisms and
guide next-line therapy in ALK+ non-small-cell lung cancer (NSCLC), but the clinical …

In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I
must accomplish a mission. If everything happens for a reason, my cancer, in particular, I …

Anlotinib, a multitarget tyrosine kinase inhibitor, is effective as a third-line treatment against
non-small cell lung cancer (NSCLC). However, acquired resistance occurs during its …

The development of cervical cancer is frequently accompanied by the integration of human
papillomaviruses (HPV) DNA into the host genome. Viral-cellular junction sequences, which …

An individual tumor can present intratumoral phenotypic heterogeneity, containing tumor
cells with different phenotypes that do not present irreversible genetic alterations. We have …

Background Liquid rebiopsies can detect resistance mutations to guide therapy of anaplastic
lymphoma kinase-rearranged (ALK+) non-small-cell lung cancer (NSCLC) failing tyrosine …